CL2023000743A1 - Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel - Google Patents

Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel

Info

Publication number
CL2023000743A1
CL2023000743A1 CL2023000743A CL2023000743A CL2023000743A1 CL 2023000743 A1 CL2023000743 A1 CL 2023000743A1 CL 2023000743 A CL2023000743 A CL 2023000743A CL 2023000743 A CL2023000743 A CL 2023000743A CL 2023000743 A1 CL2023000743 A1 CL 2023000743A1
Authority
CL
Chile
Prior art keywords
methods
subject
compositions
wounds
disorders
Prior art date
Application number
CL2023000743A
Other languages
English (en)
Inventor
Krishnan Suma
Agarwal Pooja
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57822104&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2023000743(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of CL2023000743A1 publication Critical patent/CL2023000743A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente revelación tiene relación, en parte, con composiciones farmacéuticas que comprenden uno o más polinucleótidos adecuados para potenciar, aumentar, y/o suplementar los niveles de polipéptidos de cadena de Colágeno alfa-1 (VII) y/o polipéptido de lisil hidroxilasa 3 y/o polipéptido del citoesqueleto 17 de queratina tipo I en un sujeto. La presente revelación también tiene relación, en parte, a composiciones farmacéuticas y a métodos de uso para proporcionar alivio profiláctico, paliativo o terapéutico de una herida, trastorno o enfermedad de la piel en un sujeto, incluyendo un sujeto que tiene, o está en riesgo de desarrollar, uno o más síntomas de epidermólisis ampollosa.
CL2023000743A 2016-04-08 2023-03-15 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel CL2023000743A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662320316P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
CL2023000743A1 true CL2023000743A1 (es) 2023-09-29

Family

ID=57822104

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2018002814A CL2018002814A1 (es) 2016-04-08 2018-10-03 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2021000881A CL2021000881A1 (es) 2016-04-08 2021-04-09 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814
CL2023000743A CL2023000743A1 (es) 2016-04-08 2023-03-15 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2018002814A CL2018002814A1 (es) 2016-04-08 2018-10-03 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2021000881A CL2021000881A1 (es) 2016-04-08 2021-04-09 Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel . (divisional de solicitud 201802814

Country Status (21)

Country Link
US (7) US9877990B2 (es)
EP (2) EP3377637B1 (es)
JP (3) JP6970086B2 (es)
KR (1) KR20180128016A (es)
CN (1) CN109072255A (es)
AU (3) AU2016401692B2 (es)
CA (1) CA3017487A1 (es)
CL (3) CL2018002814A1 (es)
CY (1) CY1123024T1 (es)
DK (1) DK3377637T3 (es)
ES (1) ES2796488T3 (es)
HR (1) HRP20200853T1 (es)
HU (1) HUE049237T2 (es)
LT (1) LT3377637T (es)
MX (2) MX2018012135A (es)
PL (1) PL3377637T3 (es)
PT (1) PT3377637T (es)
RS (1) RS60410B1 (es)
SG (1) SG11201808314QA (es)
SI (1) SI3377637T1 (es)
WO (1) WO2017176336A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
JP6970086B2 (ja) 2016-04-08 2021-11-24 クリスタル バイオテック，インコーポレイティド 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法
CN110312506A (zh) * 2016-11-14 2019-10-08 密歇根大学董事会 用于阻挡紫外线辐射的组合物和方法
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
MX2020005392A (es) 2017-12-07 2020-12-07 Univ Emory N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
CA3094345A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
WO2019210219A1 (en) 2018-04-27 2019-10-31 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
CA3112627A1 (en) 2018-09-24 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
CA3112633A1 (en) 2018-09-26 2020-04-02 Krystal Biotech, Inc. Compositions and methods for the treatment of skin diseases
WO2020149395A1 (ja) * 2019-01-18 2020-07-23 国立大学法人大阪大学 栄養障害型表皮水疱症治療薬
US10829529B2 (en) 2019-02-08 2020-11-10 Krystal Biotech, Inc. Compositions and methods for delivering CFTR polypeptides
EP3946596A4 (en) * 2019-03-27 2022-12-21 Phoenix Tissue Repair, Inc. SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7
EP4025699A1 (en) 2019-09-03 2022-07-13 Krystal Biotech, Inc. Compositions and methods for the treatment of congenital ichthyoses
CN112724225B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-6、制法和其药物组合物与用途
EP4077688A1 (en) 2019-12-20 2022-10-26 Krystal Biotech, Inc. Compositions and methods for gene delivery to the airways and/or lungs
CN117412986A (zh) 2021-04-02 2024-01-16 克里斯托生物技术股份有限公司 用于癌症疗法的病毒载体
WO2023064806A1 (en) 2021-10-12 2023-04-20 Phoenix Tissue Repair, Inc. Collagen 7 protein replacement therapy
CN117143223B (zh) * 2022-08-23 2024-03-08 山西锦波生物医药股份有限公司 一种生物合成人体结构性材料的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672344A (en) * 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
IL132087A0 (en) * 1997-04-10 2001-03-19 Univ Southern California Modified proteins which bind extracellular matrix components
US5998174A (en) 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
GB9715085D0 (en) * 1997-07-18 1997-09-24 Jahoda Amanda J Gene therapy vehicle
US6106826A (en) * 1997-12-17 2000-08-22 Wisconsin Alumni Research Foundation Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy
GB9801930D0 (en) * 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
WO1999064094A1 (en) * 1998-06-12 1999-12-16 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
JP2003535565A (ja) 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション 新生物疾患の治療に有用な組換え単純ヘルペスウイルス
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
AU1788502A (en) * 2000-11-28 2002-06-11 Univ Chicago Genetically engineered herpes virus for the treatment of cardiovascular disease
AU2003298786A1 (en) 2002-11-26 2004-06-18 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
CN101203530A (zh) * 2004-10-28 2008-06-18 匹兹堡大学高等教育联邦体系 关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗
RU2007131689A (ru) * 2005-01-21 2009-02-27 Интроджен Тетрапьютикс, Инк. (Us) Местное введение терапевтических и профилактических нуклеиновых кислот, обеспечивающее их пролонгированное действие на клетки-мишени
AU2006252406B2 (en) * 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
US8703703B2 (en) * 2006-12-20 2014-04-22 University Of Central Flordia Research Foundation, Inc. MCPIP as wound therapy
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US20080289058A1 (en) * 2007-05-14 2008-11-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Targeted delivery of glycine receptors to excitable cells
WO2009105690A2 (en) * 2008-02-21 2009-08-27 Targeted Genetics Corporation Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea
CN102212559B (zh) 2011-04-14 2014-04-09 郑州威瑞生物技术有限公司 一种重组的hsv扩增子载体及其用途
US9340783B2 (en) * 2011-10-11 2016-05-17 Inserm (Institut National De La Sante Et De La Recherche Medicale Exon skipping therapy for dystrophic epidermolysis bullosa
GB201202561D0 (en) 2012-02-15 2012-03-28 Univ Dundee Treatment of skin disorders
CN104768567B (zh) * 2012-05-18 2017-07-11 奥塔哥创业有限公司 用于伤口愈合的联合治疗和组合物
AU2014223243B2 (en) * 2013-03-01 2019-10-17 Regents Of The University Of Minnesota Talen-based gene correction
BR112015022868B1 (pt) * 2013-03-14 2023-05-16 Ethris Gmbh Composições de mrna de cftr e usos e métodos relacionados
WO2015009952A1 (en) * 2013-07-17 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
ES2810800T3 (es) * 2013-10-28 2021-03-09 Univ Pittsburgh Commonwealth Sys Higher Education Vector de HSV oncolítico
MX2016009771A (es) 2014-01-31 2016-11-14 Factor Bioscience Inc Metodos y productos para la produccion y administracion de acido nucleico.
GB2526339A (en) * 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
JP6925805B2 (ja) * 2014-10-31 2021-08-25 京都府公立大学法人 ラミニンによる角膜の新規治療
US20180148711A1 (en) * 2015-05-28 2018-05-31 Coda Biotherapeutics, Inc. Genome editing vectors
CN109069668B (zh) * 2015-12-14 2023-04-18 宾夕法尼亚州大学信托人 用于眼病的基因疗法
EP3432905B1 (en) * 2016-03-25 2022-06-01 PeriphaGen, Inc. Hsv vectors for delivery of nt3 and treatment of cipn
DK3432912T3 (da) * 2016-03-25 2023-03-13 Periphagen Inc Hsv-vektorer med høj transduktion
JP6970086B2 (ja) 2016-04-08 2021-11-24 クリスタル バイオテック，インコーポレイティド 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法
CA3094345A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
WO2019210219A1 (en) 2018-04-27 2019-10-31 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
JP2021529531A (ja) 2018-06-29 2021-11-04 クリスタル バイオテック インコーポレイテッド 抗体送達のための組成物及び方法

Also Published As

Publication number Publication date
AU2019280069A1 (en) 2020-01-16
US10155016B2 (en) 2018-12-18
SI3377637T1 (sl) 2020-08-31
US10441614B2 (en) 2019-10-15
JP2023118838A (ja) 2023-08-25
PL3377637T3 (pl) 2020-09-07
US20180169160A1 (en) 2018-06-21
US9877990B2 (en) 2018-01-30
HUE049237T2 (hu) 2020-09-28
AU2016401692A1 (en) 2018-09-27
US20190160122A1 (en) 2019-05-30
AU2022204729A1 (en) 2022-07-21
CL2018002814A1 (es) 2019-02-15
JP2019513689A (ja) 2019-05-30
PT3377637T (pt) 2020-06-17
MX2018012135A (es) 2019-03-28
US20220273737A1 (en) 2022-09-01
US11185564B2 (en) 2021-11-30
KR20180128016A (ko) 2018-11-30
LT3377637T (lt) 2020-07-10
EP3712273A1 (en) 2020-09-23
EP3377637A1 (en) 2018-09-26
DK3377637T3 (da) 2020-05-18
US11865148B2 (en) 2024-01-09
JP7480105B2 (ja) 2024-05-09
CN109072255A (zh) 2018-12-21
JP2022023174A (ja) 2022-02-07
US20200101123A1 (en) 2020-04-02
MX2022006072A (es) 2022-06-14
CA3017487A1 (en) 2017-10-12
US20230414686A1 (en) 2023-12-28
US20170290866A1 (en) 2017-10-12
CY1123024T1 (el) 2021-10-29
EP3377637B1 (en) 2020-03-18
JP6970086B2 (ja) 2021-11-24
ES2796488T3 (es) 2020-11-27
US20230149486A1 (en) 2023-05-18
WO2017176336A1 (en) 2017-10-12
NZ746213A (en) 2021-08-27
CL2021000881A1 (es) 2021-09-10
AU2019280069B2 (en) 2022-04-07
AU2016401692B2 (en) 2019-10-03
SG11201808314QA (en) 2018-10-30
RS60410B1 (sr) 2020-07-31
HRP20200853T1 (hr) 2020-08-21

Similar Documents

Publication Publication Date Title
CL2023000743A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
BR112017013022A2 (pt) métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
ECSP16094261A (es) Formulaciones y métodos de tratamiento con queratina
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
BR112016020618A8 (pt) oligômero antissentido, composição farmacêutica, e, uso de um oligômero antissentido
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
EA201591413A1 (ru) Композиции и способы для лечения поверхностных ран
WO2016043874A3 (en) Combination therapy for treating cancer
BR112013018919A2 (pt) composições de nanopartículas vazias e seu uso para tratamento de problemas dermatológicos
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
CL2019001415A1 (es) Composición para promover la diferenciación de y para proteger las células madre neuronales y método para inducir la regeneración neural utilizando la misma.
AR097599A1 (es) Una composición que comprende extracto de guaçatonga y aroeira, su uso y un método para la prevención y/o tratamiento de señales causadas por el envejecimiento de la piel
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
MX2018013860A (es) Composiciones cosmeticas para reparacion cutanea.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112018017233A2 (pt) uso de i. butyriciproducens e/ou e. hallii, e, composição
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
PH12016500842A1 (en) Use of cysteamine and derivatives thereof to treat mitochondrial diseases
BR112019006174A2 (pt) proteina terapêutica
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112022003867A2 (pt) Conjugado anticorpo-droga (adc), composição farmacêutica e adc para seu uso ou composição para seu uso